Log in to save to my catalogue

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum...

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d7fb152ec84945d69dcad913c8a97445

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo

About this item

Full title

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo

Publisher

England: BioMed Central Ltd

Journal title

Biology direct, 2023-04, Vol.18 (1), p.17-17, Article 17

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Malignant mesothelioma (MM) is a rare tumor with a dismal prognosis. The low efficacy of current treatment options highlights the urge to identify more effective therapies aimed at improving MM patients' survival. Bortezomib (Bor) is a specific and reversible inhibitor of the chymotrypsin-like activity of the 20S core of the proteasome, currently a...

Alternative Titles

Full title

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d7fb152ec84945d69dcad913c8a97445

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d7fb152ec84945d69dcad913c8a97445

Other Identifiers

ISSN

1745-6150

E-ISSN

1745-6150

DOI

10.1186/s13062-023-00374-w

How to access this item